Tempus AI, Inc. (NASDAQ:TEM) is highlighted as one of the AI Stocks Making Waves on Wall Street, with Canaccord Genuity analyst Kyle Mikson reiterating a Buy rating and $110.00 price target. The firm sees potential in AI deployment at scale in clinical practice driving long-term revenue growth for Tempus AI.

The research note emphasizes Tempus AI’s acquisition strategy, specifically the Ambry deal, as a means to accelerate growth by expanding testing capabilities and enhancing AI functionalities. The firm’s DCF model includes key assumptions like a 10-year revenue CAGR of 22.8% and a peak operating margin of 45.6%.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company offering AI-enabled precision medicine solutions. While seen as a viable investment, some believe there are AI stocks with greater upside potential and less downside risk. For those interested in undervalued AI stocks, a free report on the best short-term AI stock is available.

For more insights on AI stocks, check out 10 AI Stocks Analysts Are Watching Closely and 10 Trending AI Stocks on Wall Street’s Radar. Disclosure: None.

Read more at Yahoo Finance: Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine